冯建文

[摘要] 目的 分析瑞舒伐他汀联合依达拉奉对急性脑梗死患者治疗效果及炎症因子的影响。 方法 方便选取2015年3月—2016年2月淄博市中西医结合医院收治的86例急性脑梗死患者，按随机数字表法分成观察组和对照组，每组43例。对照组采用依达拉奉进行治疗，观察组在对照组的基础上给予瑞舒伐他汀。对比两组治疗效果及治疗前、后炎症因子水平。结果 观察组治疗的总有效率为95.35%明显高于对照组的81.40%（P<0.05）；观察组治疗前MMP-9及hs-CRP分别为（58.36±14.59）ng/L和（31.28±10.55）mg/L，与对照组的（57.26±15.12）ng/L和（30.59±10.64）mg/L，差异无统计学意义（P>0.05）；观察组治疗后MMP-9及hs-CRP分别为（29.32±12.61）ng/L和（15.54±8.86）mg/L，低于对照组的（38.81±14.29）ng/L和（21.93±9.72）mg/L（P<0.05）。结论 瑞舒伐他汀联合依达拉奉能有效的提高对急性脑梗死的治疗效果，并降低炎症因子水平。

[关键词] 瑞舒伐他汀；依达拉奉；急性脑梗死

[中图分类号] R5 [文献标识码] A [文章编号] 1674-0742（2017）01（c）-0117-03

Effect of Rosuvastatain and Edaravone on the Treatment Effect of Acute Cerebral Infarction and Inflammatory Factor

FENG Jian-wen

Department of Phamarcy， Hospital of Integrated TCM and Western Medicine， Zibo， Shandong Province， 255026 China

[Abstract] Objective To analyze the effect of rosuvastatain and edaravone on the treatment effect of acute cerebral infarction and inflammatory factor. Methods Convenient selection 86 cases of patients with acute cerebral infarction admitted and treated in our hospital from March 2015 to February 2016 were randomly divided into two groups with 43 cases in each， the control group were treated with edaravone， while the observation group were treated with rosuvastatain on the basis of the control group， and the treatment effect and inflammatory factor level before and after treatment were compared between the two groups. Results The total treatment effective rate in the observation group was obviously higher than that in the control group，（95.35% vs 81.40%）（P<0.05）， and the MMP-9 and hs-CRP before treatment between the observation group and the control group had no statistical significance， [（58.36±14.59）ng/L，（31.28±10.55）mg/L vs （57.26±15.12）ng/L， （30.59±10.64）mg/L]， and the MMP-9 and hs-CRP after treatment in the observation group were lower than those in the control group，[（29.32±12.61）ng/L， （15.54±8.86）mg/L vs （38.81±14.29）ng/L， （21.93±9.72）mg/L]（P<0.05）. Conclusion Rosuvastatain and edaravone can effectively improve the treatment effect of acute cerebral infarction and reduce the inflammatory factor level.

[Key words] Rosuvastatain； Edaravone； Acute cerebral infarction

急性腦梗死是中老年常见的急性脑血管病变，是由于脑局部供血障碍所致，发病率在近年来呈现明显的上升趋势[1]。高残疾率和高死亡率是急性脑梗死患者的主要特点[2]，不但给患者生存质量和生命安全形成严重威胁，且给其家庭和社会也造成巨大的经济负担。目前对急性脑梗死的治疗仍以药物为主，主要目的在于尽早控制患者的损伤，以促进神经功能的恢复。依达拉奉是治疗急性脑梗死的常用药物，获取的临床疗效令人满意。他汀类药物具有降脂、改善内皮功能和抑制血栓形成等作用。该研究采用瑞舒伐他汀联合依达拉奉对2015年3月—2016年2月收治的43例急性脑梗死患者进行治疗，现报道如下。

1 资料与方法

1.1 一般资料

方便选取该院收治的86例急性脑梗死患者按随机数字表法分成观察组和对照组，每组43例。观察组中男性23例，女性20例；……